Persistence of nevirapine in breast milk after discontinuation of treatment

Clinical Infectious Diseases

Volumn 45, Issue 3, 2007, Pages 391-394

  Bennetto Hood, Chantelle ^a   Aldrovandi, Grace M ^b   King, Jennifer R ^a   Woodman, Kyra ^a   Ashouri, Negar ^b   Acosta, Edward P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; BREAST MILK; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MILK LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; FEMALE; FUNCTIONAL LATERALITY; HIV INFECTIONS; HUMANS; MILK, HUMAN; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 34547128589     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519427     Document Type: Article

References (18)

1. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clin Pharmacokinet 1988; 14:217-40.
2. Guay LA, Musoke P, Fleming L, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNEL 012 randomised trial. Lancet 1999; 354:795-802.
3. Mirochnick M, Fenton L, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis 1998; 178:368-74.
4. Shapiro RL, Holland DL, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720-7.
5. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNEL 006). AIDS 1999; 13:479-86.
6. van Heeswijk RPG, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14:F77-82.
7. Parkin NL, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:437-43.
8. Mackie NE, Fidler S, Tamm N, et al. Clinical implications of stopping nevirapine-based antiretroviral therapy; relative pharmacokinetics and avoidance of drug resistance. HIV Med 2004; 5:180-4.
9. Eshleman SH, Mracena M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNEL 012). AIDS 2001; 15: 1951-7.
10. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20:595-9.
11. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-9.
12. McIntyre J, Martinson N. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of mother-to-child transmission (MLCL) of HIV-1 can significantly decrease the subsequent development of maternal NNRLI-resistant virus [abstract LbOrB09]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok, Thailand). 2004.
13. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 38:283-8.
14. Lee EJ, Kantor R, Zijenah L, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis 2005; 192:1260-4.
15. Viramune [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2006. Available at: http://www.viramune.com. Accessed 6 December 2007.
16. Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78:132-42.
17. Boffito Marta, Back DJ, Blaschke TF, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-35.
18. Lonnerdal B, Forsum E, Hambraeus L. A longitudinal study of the protein, nitrogen and lactose contents of human milk from Swedish well nourished mothers. Am J Clin Nutr 1976; 29:1127-30.